Literature DB >> 1697740

Anthraquinones as a new class of antiviral agents against human immunodeficiency virus.

R F Schinazi1, C K Chu, J R Babu, B J Oswald, V Saalmann, D L Cannon, B F Eriksson, M Nasr.   

Abstract

Various anthraquinones substituted with hydroxyl, amino, halogen, carboxylic acid, substituted aromatic group, and sulfonate were tested to determine their activity against human immunodeficiency virus type 1 (HIV-1) in primary human lymphocytes. Among the compounds tested, polyphenolic and/or polysulfonate substituted anthraquinones were found to possess the most potent antiviral activity. Hypericin, an anthraquinone dimer previously shown to have activity against nonhuman retroviruses also exhibited anti-HIV-1 activity in lymphocytes. the active anthraquinones inhibited HIV-1 reverse transcriptase. However, this enzyme inhibition was selective only for 1,2,5,8-tetrahydroanthraquinone and hypericin. Hypericin interacts nonspecifically with protein suggesting that this effect may dictate its inhibitory activity against the viral reverse transcriptase.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1697740     DOI: 10.1016/0166-3542(90)90071-e

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  25 in total

1.  Inhibition of HIV-1 reverse transcriptase by aryl-substituted naphto- and anthraquinones.

Authors:  T V Ilina; E A Semenova; T R Pronyaeva; A G Pokrovskii; I V Nechepurenko; E E Shults; O I Andreeva; S N Kochetkov; G A Tolstikov
Journal:  Dokl Biochem Biophys       Date:  2002 Jan-Feb       Impact factor: 0.788

2.  Alizarin glucosyl transferase activity in Streptomyces aureofaciens mutants.

Authors:  J Matĕjů; M Nohýnek
Journal:  Folia Microbiol (Praha)       Date:  1991       Impact factor: 2.099

3.  Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules.

Authors:  C M Farnet; B Wang; J R Lipford; F D Bushman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

4.  Human immunodeficiency virus type 1 cDNA integration: new aromatic hydroxylated inhibitors and studies of the inhibition mechanism.

Authors:  C M Farnet; B Wang; M Hansen; J R Lipford; L Zalkow; W E Robinson; J Siegel; F Bushman
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

5.  Identification of light-independent inhibition of human immunodeficiency virus-1 infection through bioguided fractionation of Hypericum perforatum.

Authors:  Wendy Maury; Jason P Price; Melinda A Brindley; ChoonSeok Oh; Jeffrey D Neighbors; David F Wiemer; Nickolas Wills; Susan Carpenter; Cathy Hauck; Patricia Murphy; Mark P Widrlechner; Kathleen Delate; Ganesh Kumar; George A Kraus; Ludmila Rizshsky; Basil Nikolau
Journal:  Virol J       Date:  2009-07-13       Impact factor: 4.099

Review 6.  Anti-AIDS drug development: challenges and strategies.

Authors:  P Mohan
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

7.  Hydroxylated anthraquinones produced by Geosmithia species.

Authors:  E Stodůlková; M Kolarík; Z Kresinová; M Kuzma; M Sulc; P Man; P Novák; P Marsík; P Landa; J Olsovská; M Chudícková; S Pazoutová; J Cerný; J Bella; M Flieger
Journal:  Folia Microbiol (Praha)       Date:  2009-08-02       Impact factor: 2.099

Review 8.  Anthraquinones and Derivatives from Marine-Derived Fungi: Structural Diversity and Selected Biological Activities.

Authors:  Mireille Fouillaud; Mekala Venkatachalam; Emmanuelle Girard-Valenciennes; Yanis Caro; Laurent Dufossé
Journal:  Mar Drugs       Date:  2016-03-25       Impact factor: 5.118

9.  Antiviral activities of anthraquinones, bianthrones and hypericin derivatives from lichens.

Authors:  P A Cohen; J B Hudson; G H Towers
Journal:  Experientia       Date:  1996-02-15

10.  Photodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses using hypericin and rose bengal: inhibition of fusion and syncytia formation.

Authors:  J Lenard; A Rabson; R Vanderoef
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.